Keywords
DosingPharmacokineticsBody surface areaCarboplatinPharmacologyEpirubicinMedicineEtoposideDrugClinical pharmacologyChemotherapyInternal medicineCisplatinCyclophosphamide
Affiliated Institutions
Related Publications
Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer
PURPOSE: We report the results of a prospectively randomized study that compared the combination of epirubicin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU)...
Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma
Doxorubicin (5 mg kg-1) was administered intravenously to C57 mice bearing subcutaneous B16F10 melanomas, distributing into the tumour with an area under the concentration-time ...
Phase I Trial of Carmustine Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma
PURPOSE: The major mechanism of resistance to alkylnitrosourea therapy involves the DNA repair protein O 6 -alkylguanine-DNA alkyltransferase (AGT), which removes chloroethylati...
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Purpose Preclinical studies indicate that gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE), an orally active epidermal growth factor receptor tyrosine kinase inhibitor, m...
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
Purpose To identify the optimal regimen and dosage of the oral mammalian target of rapamycin inhibitor everolimus (RAD001). Methods We performed a dose-escalation study in advan...
Publication Info
- Year
- 2001
- Type
- review
- Volume
- 19
- Issue
- 2
- Pages
- 171-177
- Citations
- 219
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
219
OpenAlex
Cite This
Michael B. Sawyer,
Mark J. Ratain
(2001).
Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing.
Investigational New Drugs
, 19
(2)
, 171-177.
https://doi.org/10.1023/a:1010639201787
Identifiers
- DOI
- 10.1023/a:1010639201787